CN103518133B - 监测和分析代谢活性分布的方法及其诊断和治疗用途 - Google Patents

监测和分析代谢活性分布的方法及其诊断和治疗用途 Download PDF

Info

Publication number
CN103518133B
CN103518133B CN201280022396.9A CN201280022396A CN103518133B CN 103518133 B CN103518133 B CN 103518133B CN 201280022396 A CN201280022396 A CN 201280022396A CN 103518133 B CN103518133 B CN 103518133B
Authority
CN
China
Prior art keywords
cell
metabolic activity
cells
cancer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280022396.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103518133A (zh
Inventor
鲁文·蒂洛希
费尔南多·帕托尔斯基
哈吉特·佩雷茨-索罗卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CN103518133A publication Critical patent/CN103518133A/zh
Application granted granted Critical
Publication of CN103518133B publication Critical patent/CN103518133B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Ecology (AREA)
CN201280022396.9A 2011-04-06 2012-04-04 监测和分析代谢活性分布的方法及其诊断和治疗用途 Active CN103518133B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472213P 2011-04-06 2011-04-06
US61/472,213 2011-04-06
PCT/IL2012/050125 WO2012137207A1 (en) 2011-04-06 2012-04-04 Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same

Publications (2)

Publication Number Publication Date
CN103518133A CN103518133A (zh) 2014-01-15
CN103518133B true CN103518133B (zh) 2016-08-17

Family

ID=46124593

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280022396.9A Active CN103518133B (zh) 2011-04-06 2012-04-04 监测和分析代谢活性分布的方法及其诊断和治疗用途

Country Status (11)

Country Link
US (3) US8728758B2 (enExample)
EP (1) EP2694962B1 (enExample)
JP (1) JP5990254B2 (enExample)
KR (1) KR102010600B1 (enExample)
CN (1) CN103518133B (enExample)
AU (1) AU2012240953B2 (enExample)
BR (1) BR112013025782B1 (enExample)
CA (1) CA2832031C (enExample)
DK (1) DK2694962T3 (enExample)
ES (1) ES2627154T3 (enExample)
WO (1) WO2012137207A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012137207A1 (en) 2011-04-06 2012-10-11 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
US20160262693A1 (en) * 2013-10-14 2016-09-15 Case Western Reserve University Metabolic analyzer for optimizing health and weight management
US10274456B2 (en) 2013-10-22 2019-04-30 Ramot At Tel-Aviv University Ltd. Method and system for sensing
ITRM20130700A1 (it) * 2013-12-19 2015-06-20 Stichting Katholieke Univ Metodo per il rilevamento di cellule tumorali circolanti
CN105303035A (zh) * 2015-09-29 2016-02-03 上海新窝信息科技有限公司 一种健康监测方法及系统
RU2018124339A (ru) 2015-12-09 2020-01-09 Рамот Ат Тель-Авив Юниверсити Лтд. Способ и система для сенсорного обнаружения посредством модифицированной наноструктуры
RU2019108155A (ru) 2016-08-22 2020-09-21 Рамот Эт Тель-Авив Юниверсити Лтд. Способ и система для подкожного сенсорного определения
US11906463B2 (en) 2016-08-22 2024-02-20 Ramot At Tel-Aviv University Ltd. Methods and systems for detecting bioanalytes
JP7356412B2 (ja) 2017-08-21 2023-10-04 サヴィセル ダイアグノスティック リミテッド 肺癌を検出する方法
CN110491511B (zh) * 2019-07-24 2023-04-07 广州知汇云科技有限公司 一种基于围术期危险预警的多模型互补增强机器学习方法
IT202000016429A1 (it) * 2020-07-07 2022-01-07 Univ Degli Studi Udine Metodo per la valutazione dell’attivita’ metabolica di una cellula non-tumorale
EP4251997A4 (en) * 2020-11-26 2025-07-23 12535441 Canada Ltd SPECTRAL DIAGNOSTIC SYSTEM
US20240358835A1 (en) * 2021-08-17 2024-10-31 Orgenesis Inc. Tumor infiltrating lymphocytes with increased metabolic activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008018905A2 (en) * 2006-01-17 2008-02-14 Cellumen, Inc. Method for predicting biological systems responses
CN101213455A (zh) * 2005-06-24 2008-07-02 埃佩多夫阵列技术股份有限公司 用于检测和/或定量细胞在响应外在刺激时的等级分子变化的方法和工具

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2457391A1 (en) * 2001-08-06 2003-02-20 Vanderbilt University Device and methods for detecting the response of a plurality of cells to at least one analyte of interest
JP4625946B2 (ja) * 2004-11-02 2011-02-02 国立大学法人 岡山大学 ｐＨ測定装置及びｐＨ測定方法
WO2007102146A2 (en) 2006-03-06 2007-09-13 Zetiq Technologies Ltd. Methods and compositions for identifying a cell phenotype
WO2011000572A1 (de) * 2009-07-02 2011-01-06 Patenthandel Portfoliofonds I Gmbh & Co. Kg Verfahren und vorrichtung zum nachweis von biologischen langzeiteffekten in zellen
EP2476053A4 (en) * 2009-09-08 2014-03-12 Nodality Inc ANALYSIS OF CELL NETWORKS
WO2012137207A1 (en) 2011-04-06 2012-10-11 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101213455A (zh) * 2005-06-24 2008-07-02 埃佩多夫阵列技术股份有限公司 用于检测和/或定量细胞在响应外在刺激时的等级分子变化的方法和工具
WO2008018905A2 (en) * 2006-01-17 2008-02-14 Cellumen, Inc. Method for predicting biological systems responses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
In vitro analysis of cell metabolism using a long-decay pH-sensitive lanthanide probe and extracellular acidification assay;Hynes J et al.;《Anal Biochem》;20090701;第390卷(第1期);摘要，第21页左栏至第23页左栏第3段，第24页右栏第2段至第25页左栏，第26页左栏第3段，第26页右栏，第28页左栏，图3-5，表1 *

Also Published As

Publication number Publication date
US20140255972A1 (en) 2014-09-11
CN103518133A (zh) 2014-01-15
ES2627154T3 (es) 2017-07-26
BR112013025782B1 (pt) 2022-09-06
BR112013025782A2 (pt) 2016-12-20
JP5990254B2 (ja) 2016-09-07
CA2832031C (en) 2019-09-17
EP2694962B1 (en) 2017-03-01
EP2694962A1 (en) 2014-02-12
CA2832031A1 (en) 2012-10-11
AU2012240953B2 (en) 2017-02-23
KR102010600B1 (ko) 2019-08-13
US9784731B2 (en) 2017-10-10
DK2694962T3 (en) 2017-06-12
WO2012137207A1 (en) 2012-10-11
JP2014512006A (ja) 2014-05-19
US20130224789A1 (en) 2013-08-29
KR20140024871A (ko) 2014-03-03
US20180038849A1 (en) 2018-02-08
US8728758B2 (en) 2014-05-20
AU2012240953A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
CN103518133B (zh) 监测和分析代谢活性分布的方法及其诊断和治疗用途
Wisdom et al. Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy
Liu et al. Dendritic cell type 3 arises from Ly6C+ monocyte-dendritic cell progenitors
Wei et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Ferreira et al. Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity
McEvoy et al. Single-cell profiling of healthy human kidney reveals features of sex-based transcriptional programs and tissue-specific immunity
Atwa et al. T‐helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor‐α) in patients with alopecia areata: association with clinical type and severity
Fagone et al. VGX‐1027 modulates genes involved in lipopolysaccharide‐induced T oll‐like receptor 4 activation and in a murine model of systemic lupus erythematosus
Wcisło-Dziadecka et al. Influence of adalimumab on the expression profile of genes associated with the histaminergic system in the skin fibroblasts in vitro
Pant et al. Monocytes in type 1 diabetes families exhibit high cytolytic activity and subset abundances that correlate with clinical progression
Lee et al. Use of a platform with lens-free shadow imaging technology to monitor natural killer cell activity
Zivanovic et al. Single‐cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants
Ridge et al. Lin− CD117+ CD34+ FcεRI+ progenitor cells are increased in chronic spontaneous urticaria and predict clinical responsiveness to anti‐IgE therapy
Zeng et al. Efficient Predictor for Immunotherapy Efficacy: Detecting Pan‐Clones Effector Tumor Antigen‐Specific T Cells in Blood by Nanoparticles Loading Whole Tumor Antigens
US20110312016A1 (en) Method for Evaluating Immunosuppression
Schroeder et al. Novel human kidney cell subsets identified by Mux-Seq
Lee et al. The role of plasma cell-free mitochondrial DNA and nuclear DNA in systemic lupus erythematosus
Prieto et al. Increased spontaneous ex vivo apoptosis and subset alterations in peripheral blood T cells from patients with multiple sclerosis
Sameir et al. The increased frequency of type 1 regulatory T (Tr1) cells and the altered expression of aryl hydrocarbon receptor (AHR) and interferon regulatory factor-4 (IRF4) genes in type 1 diabetes: a case-control study
Markov et al. Profibrotic monocyte-derived alveolar macrophages as a biomarker and therapeutic target in systemic sclerosis-associated interstitial lung disease
Gueguen et al. Contribution of resident and circulating precursors to tumor-infiltrating CD8+ T cell populations in non-small cell lung cancer patients
Lechner et al. Inhibition of the IL-17A axis Protects against Immune-related Adverse Events while Supporting Checkpoint Inhibitor Anti-tumor Efficacy
US12462941B2 (en) Pan-cancer tumor microenvironment classification based on immune escape mechanisms and immune infiltration
Singh et al. Decoding functional and developmental trajectories of tissue-resident uterine dendritic cells through integrative omics
Cardinez IKBKB Gain-of-Function in human disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant